{Reference Type}: Journal Article
{Title}: Development and therapeutic perspectives of CXCR4 antagonists for disease therapy.
{Author}: Yang J;Tian E;Chen L;Liu Z;Ren Y;Mao W;Zhang Y;Zhang J;
{Journal}: Eur J Med Chem
{Volume}: 275
{Issue}: 0
{Year}: 2024 Jun 11
{Factor}: 7.088
{DOI}: 10.1016/j.ejmech.2024.116594
{Abstract}: Chemokine receptor 4 (CXCR4) is a subtype receptor protein of the GPCR family with a seven-transmembrane structure widely distributed in human tissues. CXCR4 is involved in diseases (e.g., HIV-1 infection), cancer proliferation and metastasis, inflammation signaling pathways, and leukemia, making it a promising drug target. Clinical trials on CXCR4 antagonists mainly focused on peptides and antibodies, with a few small molecule compounds, such as AMD11070 (2) and MSX-122 (3), showing promise in cancer treatment. This perspective discusses the structure-activity relationship (SAR) of CXCR4 and its role in diseases, mainly focusing on the SAR of CXCR4 antagonists. It also explores the standard structural features and target interactions of CXCR4 binding in different disease categories. Furthermore, it investigates various modification strategies to propose potential improvements in the effectiveness of CXCR4 drugs.